

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2024/186418 A1

(43) International Publication Date
12 September 2024 (12.09.2024)

(51) International Patent Classification:

A61K 38/17 (2006.01) C07K 14/71 (2006.01)
A61K 38/18 (2006.01) C07K 19/00 (2006.01)

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/US2024/013378

(22) International Filing Date:

29 January 2024 (29.01.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/451,198 09 March 2023 (09.03.2023) US

(71) Applicant: **MERCK SHARP & DOHME LLC** [US/US];
126 East Lincoln Avenue, Rahway, NJ 07065 (US).

(72) Inventors: **SADINENI, Vikram**; c/o Merck Sharp &
Dohme LLC, 126 East Lincoln Avenue, Rahway, NJ 07065
(US). **BHIWANKAR, Meena Nikhil**; c/o Merck Sharp &
Dohme LLC, 126 East Lincoln Avenue, Rahway, NJ 07065
(US). **LIU, Xiaoqing**; c/o Merck Sharp & Dohme LLC, 126
East Lincoln Avenue, Rahway, NJ 07065 (US).

(74) Agent: **VARMA, Anita** et al.; White & Case LLP, 75 State
Street, Boston, MA 02109 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: FORMULATIONS COMPRISING ACTRIIA POLYPEPTIDE VARIANTS

(57) Abstract: In certain aspects, the present disclosure provides lyophilized pharmaceutical formulations comprising a recombinant fusion protein comprising an extracellular domain (ECD) of human activin receptor type-IIA (ActRIIa) proteins or derivatives thereof linked to a constant domain of an immunoglobulin, such as human IgG1 Fc domain and one or more pharmaceutical additives and/or excipients.

WO 2024/186418 A1